FMP

FMP

Enter

ABVX.PA - ABIVAX Société Anony...

Financial Summary of ABIVAX Société Anonyme(ABVX.PA), ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, inf

photo-url-https://financialmodelingprep.com/image-stock/ABVX.PA.png

ABIVAX Société Anonyme

ABVX.PA

EURONEXT

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

13.96 EUR

0.18 (1.29%)

About

ceo

Mr. Marc M. P. de Garidel M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.abivax.com

exchange

EURONEXT

Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengu...

CIK

N/A

ISIN

FR0012333284

CUSIP

N/A

Address

5, rue de la Baume

Phone

33 1 53 83 08 41

Country

FR

Employee

61

IPO Date

Jun 26, 2015

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

-

ISIN

FR0012333284

Country

FR

Price

13.96

Beta

1.46

Volume Avg.

35.87k

Market Cap

878.01M

Shares

-

52-Week

7.89-19.7

DCF

1.54

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.07

P/B

-

Website

https://www.abivax.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ABVX.PA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep